Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
TLSI Quote, Financials, Valuation and Earnings
Last price:
$7.06
Seasonality move
:
29.79%
Day range:
$6.99 - $7.28
52-week range:
$3.42 - $7.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.80x
P/B ratio:
--
Volume:
32.7K
Avg. volume:
211.2K
1-year change:
48.63%
Market cap:
$352.7M
Revenue:
$29.4M
EPS (TTM):
-$2.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$11.8M | -$0.17 | 55.01% | -67.11% | $11.50 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
ICUI
ICU Medical, Inc.
|
$511.5M | $1.43 | -13.68% | 316.67% | $180.83 |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$7.06 | $11.50 | $352.7M | -- | $0.00 | 0% | 5.80x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8150 | $12.3077 | $209.3M | -- | $0.00 | 0% | 190.87x |
|
ICUI
ICU Medical, Inc.
|
$146.98 | $180.83 | $3.6B | -- | $0.00 | 0% | 1.56x |
|
VNRX
VolitionRX Ltd.
|
$0.25 | $2.20 | $30.9M | -- | $0.00 | 0% | 17.27x |
|
VTAK
Catheter Precision, Inc.
|
$1.78 | -- | $2.2M | 0.40x | $0.00 | 0% | 8.37x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $108.9M | 76.27x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
461.2% | -0.594 | 14.71% | 2.54x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
ICUI
ICU Medical, Inc.
|
39.35% | 0.320 | 46.61% | 1.02x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$9.7M | -$9M | -936.41% | -- | -77.94% | -$3.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ICUI
ICU Medical, Inc.
|
$202.3M | $28.3M | -0.21% | -0.36% | 5.26% | $25M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
TriSalus Life Sciences, Inc. vs. Competitors
-
Which has Higher Returns TLSI or CATX?
Perspective Therapeutics, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -12425.36%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About TLSI or CATX?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 62.89%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is TLSI or CATX More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock TLSI or CATX?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or CATX?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. TriSalus Life Sciences, Inc.'s net income of -$10.8M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.80x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.80x -- $11.6M -$10.8M CATXPerspective Therapeutics, Inc.190.87x -- $209K -$26M
-
Which has Higher Returns TLSI or ICUI?
ICU Medical, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -0.63%. TriSalus Life Sciences, Inc.'s return on equity of -- beat ICU Medical, Inc.'s return on equity of -0.36%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M ICUIICU Medical, Inc.37.63% -$0.14 $3.5B -
What do Analysts Say About TLSI or ICUI?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 62.89%. On the other hand ICU Medical, Inc. has an analysts' consensus of $180.83 which suggests that it could grow by 23.03%. Given that TriSalus Life Sciences, Inc. has higher upside potential than ICU Medical, Inc., analysts believe TriSalus Life Sciences, Inc. is more attractive than ICU Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 ICUIICU Medical, Inc.3 1 0 -
Is TLSI or ICUI More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ICU Medical, Inc. has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.719%.
-
Which is a Better Dividend Stock TLSI or ICUI?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. ICU Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or ICUI?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than ICU Medical, Inc. quarterly revenues of $537.7M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than ICU Medical, Inc.'s net income of -$3.4M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while ICU Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.80x versus 1.56x for ICU Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.80x -- $11.6M -$10.8M ICUIICU Medical, Inc.1.56x -- $537.7M -$3.4M
-
Which has Higher Returns TLSI or VNRX?
VolitionRX Ltd. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -862.39%. TriSalus Life Sciences, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About TLSI or VNRX?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 62.89%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe VolitionRX Ltd. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is TLSI or VNRX More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock TLSI or VNRX?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or VNRX?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.80x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.80x -- $11.6M -$10.8M VNRXVolitionRX Ltd.17.27x -- $627.3K -$5.4M
-
Which has Higher Returns TLSI or VTAK?
Catheter Precision, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -1037.17%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About TLSI or VTAK?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 62.89%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 2034.9%. Given that Catheter Precision, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Catheter Precision, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is TLSI or VTAK More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
-
Which is a Better Dividend Stock TLSI or VTAK?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or VTAK?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.80x versus 8.37x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.80x -- $11.6M -$10.8M VTAKCatheter Precision, Inc.8.37x 0.40x $226K -$2.3M
-
Which has Higher Returns TLSI or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of 3.93%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About TLSI or XTNT?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 62.89%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Xtant Medical Holdings, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is TLSI or XTNT More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock TLSI or XTNT?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or XTNT?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 5.80x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.5.80x -- $11.6M -$10.8M XTNTXtant Medical Holdings, Inc.0.85x 76.27x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
